Vaccine biotechnology represents the application of advanced molecular and cellular techniques to develop, produce, and optimize vaccines. Traditional vaccine production often involved using weakened or inactivated forms of pathogens. In contrast, biotechnology allows for the creation of vaccines using specific genetic material, proteins, or subunits associated with the target pathogen. Recombinant DNA technology enables the insertion of genes encoding pathogenic proteins into host cells, such as yeast or bacteria, to produce large quantities of antigenic proteins for vaccine development. This approach enhances precision and safety in vaccine design. The advent of mRNA vaccine technology, exemplified by COVID-19 vaccines, represents a groundbreaking application of biotechnology. mRNA vaccines provide a platform for rapid response to emerging infectious diseases by delivering genetic instructions to cells, prompting them to produce viral proteins and induce an immune response. Biotechnological advancements also enable the development of subunit vaccines, virus-like particles, and vector-based vaccines. These approaches enhance the specificity, safety, and scalability of vaccine production, contributing to the development of novel vaccines against a wide range of infectious diseases. Ongoing research in vaccine biotechnology continues to revolutionize the field, offering innovative solutions for global health challenges.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey